This article is available to subscribers. Subscribe now. Already have an account? Sign in

EditorialFree Preview

Drawing the Line on Glycemia in Pregnancy

List of authors.
  • Michael F. Greene, M.D.

In the first decade of this millennium, convincing data showing that screening for and treatment of gestational diabetes mellitus improve both maternal and fetal outcomes1,2 ended debates within the obstetrical community about the usefulness of screening for gestational diabetes. Essentially all U.S. professional societies now recommend universal biochemical screening with an oral glucose-tolerance test (OGTT) at 24 to 28 weeks’ gestation.3 Accordingly, current research aims to improve the benefits of screening for gestational diabetes and to minimize potential harms. Although some sources have recommended glucose-tolerance testing in early pregnancy for women at high risk for diabetes,4 a recent randomized trial . . .

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org.

Author Affiliations

From the Department of Obstetrics and Gynecology, Harvard Medical School, Boston.